Bio Solution Co.,Ltd.
Research Bio Solution Co.,Ltd. (086820.KQ) on Bullrun: market cap KRW 155.08B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker086820.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 155.08B
- Financial periodQ2 2026
- RevenueKRW 4.70B
- Net income-KRW 736.04M
- Free cash flowKRW 252.98M
- Gross margin69.3%
Valuation Snapshot
latest market cap is KRW 155.08B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 155.08B | n/a | n/a | n/a |
Dividend history
About Bio Solution Co.,Ltd.
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-based therapy for skin wounds.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bio Solution Co.,Ltd.'s market cap?
Bio Solution Co.,Ltd.'s market capitalization is KRW 155.08B.
What does Bio Solution Co.,Ltd. do?
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-based therapy for skin wounds.